<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979966</url>
  </required_header>
  <id_info>
    <org_study_id>C-II-006 / 2009-010143-13</org_study_id>
    <nct_id>NCT00979966</nct_id>
  </id_info>
  <brief_title>Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib</brief_title>
  <official_title>Prospective Randomized Phase-II Trial With Temsirolimus Versus Sunitinib in Previously Untreated Patients With Advanced or Metastatic Non-Clear Cell Renal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Society for Anticancer Drug Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Society for Anticancer Drug Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective, open-label, randomized multicenter phase-II study to evaluate&#xD;
      progression free survival (PFS) in patients with locally advanced or metastatic non-clear&#xD;
      cell renal cell cancer (ncc-RCC) receiving Temsirolimus in comparison to Sunitinib.&#xD;
&#xD;
      In most clinical trials in renal cell carcinoma (RCC), clear cell RCC have been included&#xD;
      exclusively. There are only some limited data on the efficacy of Temsirolimus or Sunitinib in&#xD;
      ncc-RCC showing interesting response rates for both agents. However, randomized clinical&#xD;
      trials in this specific patient population have not yet been performed.&#xD;
&#xD;
      In the proposed study a comparison Temsirolimus and Sunitinib is scheduled in first line&#xD;
      therapy of ncc-RCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>7-11 months expected</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>7-11 months expected</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety assessed using CTCAE v3.0 and safety assessed according to reported SAEs</measure>
    <time_frame>8-12 months (treatment duration + 1 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>one year progression free survival rate (1YPFSR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>will be evaluated in 2013</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Non-clear Cell Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temsirolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>25 mg intravenously, once weekly infusion</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg oral once daily for 4 weeks, followed by 2 weeks rest.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult males and females: ≥18 years of age.&#xD;
&#xD;
          2. Locally advanced or metastatic, histological confirmed, non-clear cell RCC of all&#xD;
             subtypes. Patients must have advanced non-clear cell of one of the following subtypes:&#xD;
             papillary, chromophobe, collecting duct carcinoma (CDC), renal medullary carcinoma&#xD;
             (RMC), or unclassified.&#xD;
&#xD;
          3. Patients with measurable disease (at least one uni-dimensionally measurable target&#xD;
             lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST 1.1) If prior palliative radiotherapy to metastatic lesions: ≥ 1 measurable&#xD;
             lesion that has not been irradiated.&#xD;
&#xD;
          4. PS 0-2 ECOG&#xD;
&#xD;
          5. Signed written informed consent.&#xD;
&#xD;
          6. White blood cell count (WBC) ≥4x10*9/L with neutrophils ≥1.5 x 10*9/L, platelet count&#xD;
             ≥100x10*9/L, hemoglobin ≥9 g/dL.]&#xD;
&#xD;
          7. Total bilirubin &lt;2 x upper limit of normal.&#xD;
&#xD;
          8. AST and ALT &lt;2.5 x upper limit of normal, or &lt;5 x upper limit of normal in case of&#xD;
             liver metastases.&#xD;
&#xD;
          9. Serum creatinine &lt;2.0 x upper limit of normal.&#xD;
&#xD;
         10. Normal ECG without QT prolongation (QTc &lt; 450msec).&#xD;
&#xD;
         11. Adequate cardiac function (left ventricular ejection fraction &gt; 40% as assessed by&#xD;
             ECHO.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Predominant clear-cell RCC&#xD;
&#xD;
          2. Resectability or other curative options&#xD;
&#xD;
          3. Any investigational drug within the 30 days before inclusion.&#xD;
&#xD;
          4. Prior systemic treatment for their RCC.&#xD;
&#xD;
          5. Known or suspected allergy or hypersensitivity reaction to any of the components of&#xD;
             study treatments.&#xD;
&#xD;
          6. Radiotherapy within the last 4 weeks.&#xD;
&#xD;
          7. Pregnancy (absence to be confirmed by beta-hCG test) or lactation period.&#xD;
&#xD;
          8. Men or women of child-bearing potential who are sexually active and unwilling to use a&#xD;
             medically acceptable method of contraception during the trial.&#xD;
&#xD;
          9. Clinically symptomatic brain or meningeal metastasis. (known or suspected)&#xD;
&#xD;
         10. Cardiac arrhythmias requiring anti-arrhythmics (excluding beta blockers or digoxin).&#xD;
&#xD;
         11. History of any of the following cardiac events within the past 6 months:&#xD;
&#xD;
               -  myocardial infarction (including severe/unstable angina),&#xD;
&#xD;
               -  coronary/peripheral artery bypass graft,&#xD;
&#xD;
               -  congestive heart failure (CHF),&#xD;
&#xD;
               -  cerebrovascular accident,&#xD;
&#xD;
               -  transient ischemic attack,&#xD;
&#xD;
               -  pulmonary embolism.&#xD;
&#xD;
         12. No hemorrhage ≥ grade 3 within the past 4 weeks&#xD;
&#xD;
         13. Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 90&#xD;
             mm Hg despite the use of ≥3 anti-hypertensive drugs&#xD;
&#xD;
         14. History of relevant pulmonary hypertension or interstitial lung disease.&#xD;
&#xD;
         15. Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or&#xD;
             chronic diarrhea&#xD;
&#xD;
         16. Previous malignancy (other than renal cancer cancer) in the last 5 years except basal&#xD;
             cell cancer of the skin, pre-invasive cancer of the cervix or superficial bladder&#xD;
             tumor [Ta, Tis and T1].&#xD;
&#xD;
         17. History of organ allograft&#xD;
&#xD;
         18. Significant disease which, in the investigator's opinion would exclude the patient&#xD;
             from the study&#xD;
&#xD;
         19. Patients with seizure and epileptic disorder or other conditions requiring medication&#xD;
             (such as phenytoin, carbamazepin, phenobarbital)&#xD;
&#xD;
         20. Patients under strong inducers or inhibitors to CYP Isoenzymes&#xD;
&#xD;
         21. Patients with hypersensitivity to the antihistamine or patients who cannot receive the&#xD;
             antihistamine for other medical reasons&#xD;
&#xD;
         22. Patients requiring long-term cortisone therapy&#xD;
&#xD;
         23. Patients requiring oral anticoagulation treatment, such as marcoumar. (Anticoagulation&#xD;
             treatment with heparin or low molecular weight heparin [LMWH] is allowed provided that&#xD;
             close monitoring is performed).&#xD;
&#xD;
         24. Surgery within at least 2 weeks prior to randomization&#xD;
&#xD;
         25. HIV seropositivity.&#xD;
&#xD;
         26. Abnormal pulmonary function (DLCO &lt; 50%). [Pulmonary function tests need only to be&#xD;
             performed if abnormal pulmonary function present in medical history].&#xD;
&#xD;
         27. Poorly controlled diabetes mellitus.&#xD;
&#xD;
         28. Liver cirrhosis, chronic hepatitis&#xD;
&#xD;
         29. Legal incapacity or limited legal capacity&#xD;
&#xD;
         30. Known alcohol or drug abuse.&#xD;
&#xD;
         31. Medical or psychological conditions that would not permit the patient to complete the&#xD;
             study or sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charité - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum am Urban</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Kliniken Bonn gGmbH - Johanniter-Krankenhaus</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universität</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskrankenhaus Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK-SH Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Innere Medizin,</name>
      <address>
        <city>Viersen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Nordoberpfalz AG - Klinikum Weiden</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.cesar.or.at/</url>
    <description>German description on the CESAR homepage</description>
  </link>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced or metastatic non-clear cell renal cell cancer (ncc-RCC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

